Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Atossa Therapeutics presented preclinical data on its lead candidate (Z)-endoxifen at the AACR Special Conference in Vancouver, focusing on McCune-Albright Syndrome. The poster details a dual mechanism of action, blocking estrogen receptor signaling and suppressing PKC-β/AKT pathways to address downstream proliferative signaling. CEO Dr.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.